EXHIBIT 10.102*
MANUFACTURING AGREEMENT
This MANUFACTURING AGREEMENT is entered into as of August 21, 1996, by and
between DURA PHARMACEUTICALS, INC. ("Dura"), a corporation organized and
existing under the laws of the State of California, with offices at ▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇, ▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇-▇▇▇▇ and ▇▇▇ ▇▇▇▇▇ AND COMPANY
("Lilly"), a corporation organized and existing under the laws of the State of
Indiana, with offices at Lilly ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇▇▇▇▇.
RECITALS
1. Subject to the terms and conditions set forth in this Agreement, Dura
wishes to have Lilly manufacture for Dura certain anti-infective pharmaceutical
products; and
2. Subject to the terms and conditions set forth in this Agreement, Lilly
wishes to manufacture such anti-infective pharmaceutical products for Dura.
NOW, THEREFORE, the parties hereto, intending to be legally bound, hereby
agree as follows:
SECTION 1
DEFINITIONS
For purposes of this Agreement, the following terms shall have the meanings
set forth below:
"AFFILIATES" shall mean, with respect to any Person, any Persons directly
or indirectly controlling, controlled by, or under common control with, such
other Person. For purposes hereof, the term "controlled" (including the terms
"controlled by" and "under common control with"), as used with respect to any
Person, shall mean the direct or indirect ability or power to direct or cause
the direction of management policies of such Person or otherwise direct the
affairs of such Person, whether through ownership of voting securities or
otherwise.
--------------------------------------
* CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED BY MEANS OF MARKING
SUCH PORTIONS WITH AN ASTERISK (THE "▇▇▇▇"). THIS EXHIBIT HAS BEEN FILED WITH
THE SECRETARY OF THE COMMISSION WITHOUT THE ▇▇▇▇ PURSUANT TO THE COMPANY'S
APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
"APPLICABLE LAWS" shall mean all applicable federal, state and local laws,
ordinances, rules and regulations of any kind whatsoever, including, without
limitation, the Federal Food, Drug and Cosmetic Act.
"BULK PATENTS" shall have the meaning given in Section 1 of the Licensing
Agreement.
"BULK TECHNOLOGY" shall have the meaning given in Section 1 of the
Licensing Agreement.
"CLOSING DATE" shall have the meaning given in Section 4.3 of the Licensing
Agreement.
"DAMAGES" shall mean any and all costs, losses, claims, liabilities, fines,
penalties, damages and expenses, court costs, and reasonable fees and
disbursements of counsel, consultants and expert witnesses incurred by a party
hereto (including interest which may be imposed in connection therewith).
"FDA" shall mean the United States Food and Drug Administration.
"GOOD MANUFACTURING PRACTICES" or "GMP" shall mean current Good
Manufacturing Practices as defined in 21 CFR Section 210 ET SEQ., as amended.
"LICENSED ASSETS" shall have the meaning given in Section 2.1 of the
Licensing Agreement.
"LICENSING AGREEMENT" shall mean the Licensing Agreement, dated as of the
date of this Agreement, between Lilly and Dura, which provides for the licensing
of certain rights by Lilly to Dura in connection with the Products for the
period specified therein.
"NDAS" shall mean, with respect to Ceclor-Registered Trademark- CD
(cefaclor extended release tablets), New Drug Application Number 50-673, and,
with respect to Keftab-Registered Trademark- (cephalexin hydrochloride), New
Drug Application Number 50-614, each as filed by Lilly with the FDA and all
subsequent submissions thereto.
-2-
"PERSON" shall mean a natural person, a corporation, a partnership, a
trust, a joint venture, a limited liability company, any governmental authority
or any other entity or organization.
"PRODUCT PATENTS" shall have the meaning given in Section 1 of the
Licensing Agreement.
"PRODUCT TECHNOLOGY" shall have the meaning given in Section 1 of the
Licensing Agreement.
"PRODUCTS" shall mean those products listed in EXHIBIT A attached hereto.
"PURCHASE ORDER" shall mean a purchase order from Dura to Lilly for any of
the Products issued in accordance with the provisions of the Requirements
Document.
"REQUIREMENTS DOCUMENT" shall mean the Manufacturing Requirements Document
attached hereto as APPENDIX A, as amended from time to time, setting forth
various manufacturing and operational terms and procedures for implementing this
Agreement.
"SPECIFICATIONS" shall mean the specifications for manufacturing and
testing each of the Products and the related methods and stability protocols and
procedures as set forth in the approved NDAs and any supplements and amendments
thereto.
"UNITED STATES" shall mean the fifty (50) states and the District of
Columbia comprising the United States of America.
SECTION 2
PURCHASING, PRICING, AND PAYMENT
2.1. PURCHASE OF EXISTING INVENTORY AND CONTRIBUTION OF EXISTING
SAMPLES. Dura shall purchase Lilly's inventory of the Products existing as of
the Closing Date in the quantities and at the prices set forth in EXHIBIT B
-3-
attached hereto. Dura shall also purchase at such time Ceclor CD samples in the
quantity and at the price set forth in EXHIBIT B. In addition, Lilly shall
contribute to Dura samples in the quantities and on the dates set forth in
EXHIBIT B. Dating shall be as follows:
(a) with respect to existing Ceclor CD samples, the
expiration date shall be no earlier than June 30, 1997
(Dura agrees to make a good faith effort to distribute
these while in date.);
(b) with respect to the initial *** sample units of
existing Keftab samples, the expiration date shall be
no earlier than October 31, 1997; and
(c) with respect to existing Keftab trade inventory, the
expiration date shall be no earlier than August 31,
1997 (Dura agrees to make a good faith effort to
distribute these while in date.).
2.2. PURCHASE AND PRICE OF FUTURE PRODUCTS AND SAMPLES. Dura shall
purchase from Lilly all its requirements for future Products and samples at the
prices set forth in EXHIBIT C attached hereto. Dating shall be as follows:
(a) with respect to all future purchases of Ceclor CD
samples and trade bottles, the expiration date shall be
no earlier than eighteen (18) months from the date of
shipment; and
(b) with respect to all future purchases of Keftab samples
and trade bottles, the expiration date shall be no
earlier than sixteen (16) months from the date of
shipment.
2.3. PURCHASE ORDERS. Dura shall provide Lilly with Purchase Orders in
accordance with the Requirements Document. Each Purchase Order shall be
governed by the terms of this Agreement and none of the terms or conditions of
Dura's Purchase Orders, Lilly's acknowledgment forms or any other forms shall be
applicable, except those specifying quantity ordered, delivery locations and
delivery schedule and invoice information. Each Purchase Order shall constitute
a binding obligation upon Dura to accept and pay for the quantities of Products
ordered therein if, and to the extent that, such Products meet the
Specifications.
-4-
--------------------------------------
* CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED BY MEANS OF MARKING
SUCH PORTIONS WITH AN ASTERISK (THE "▇▇▇▇"). THIS EXHIBIT HAS BEEN FILED WITH
THE SECRETARY OF THE COMMISSION WITHOUT THE ▇▇▇▇ PURSUANT TO THE COMPANY'S
APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
2.4. TERMS OF PAYMENT. Dura agrees to pay for all invoices within thirty-
five (35) days from the date of the applicable invoice at the prices computed in
accordance with the Requirements Document. All payments to Lilly shall be made
by check or bank draft to the following address and shall indicate to which
invoice(s) payment applies:
▇▇▇ ▇▇▇▇▇ and Company
▇.▇. ▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇-▇▇▇▇
2.5. TRANSITION PLAN. Dura shall perform its obligations set forth in
the Transition Plan attached hereto as APPENDIX B.
2.6. AUDITS. The ability to conduct audits shall be provided under
and pursuant to and in accordance with the terms of Section 3.4 of the Licensing
Agreement, which terms are by this reference incorporated in and made a part of
this Agreement, and all of which for purposes of this Agreement shall survive
any termination or expiration of the Licensing Agreement.
SECTION 3
OBLIGATIONS OF LILLY
3.1. MANUFACTURING; REQUIREMENTS; DELIVERY.
(a) Lilly, or a third party under subcontract with Lilly
(subject to receipt of any required FDA approvals),
shall manufacture, package, label, test, prepare for
shipment and ship Products to Dura at and from Lilly's
facilities at the times and in the quantities set forth
by Dura in the Purchase Orders and as provided for in
the Requirements Document. Each shipment of Products
shall include a certificate of analysis confirming that
the Products therein meet the Specifications.
-5-
3.2. QUALITY CONTROL AND ASSURANCE.
(a) Lilly, or a third party under subcontract with Lilly
(subject to receipt of any required FDA approvals),
shall manufacture the Products in full compliance with
the approved NDAs and in accordance with all Applicable
Laws. Lilly shall perform quality control and quality
assurance testing on Products to be delivered to Dura
hereunder in accordance with the Specifications and the
Requirements Document.
(b) Personnel from Dura shall, upon reasonable advance
notice to Lilly, have access during normal business
hours to Lilly's premises where the Products are being
manufactured, tested, inspected, packaged and/or stored
to observe and inspect the manufacturing, quality
control and testing processes for, and the records of
all production and quality assurance data related to,
the Products. Personnel from Lilly shall have the same
rights provided to personnel from Dura under this
Section 3.2(b) if, prior to Lilly's transfer of the
Licensed Assets to Dura pursuant to Section 2.4 of the
Licensing Agreement, Dura (or a third party sublicensee
of Dura) is manufacturing either or both of the
Products.
3.3. RECORDS AND ACCOUNTING BY LILLY. Lilly shall, with respect to
each lot of the Products produced by it hereunder, for a period of three (3)
years after the expiry of the expiration dating of such lot, keep accurate
records of the manufacture and testing of the Products produced by it hereunder,
including, without limitation, all such records which are required under
Applicable Laws. Access to such records shall be made available by Lilly to
Dura upon Dura's request.
3.4. TRANSITION PLAN. Lilly shall perform its obligations set forth
in the Transition Plan attached hereto as APPENDIX B.
-6-
SECTION 4
LABELING AND TESTING PRODUCTS
4.1. LABELING AND PACKING. The Products shall be labeled, prepared
and packed for shipment in full compliance with the approved NDAs, all
Applicable Laws, and in accordance with the Requirements Document.
4.2. LOT NUMBERING. Lot numbers shall be affixed on the containers
for the Products and on each shipping carton in accordance with Applicable Laws,
Lilly's customary practice, and in accordance with the Requirements Document.
4.3. TESTING AND REJECTION OF DELIVERED PRODUCTS.
(a) Dura shall be entitled, at its cost and expense, to
test any and all Products delivered to it hereunder to
determine whether such Products comply with the
Specifications. Dura shall notify Lilly in writing
promptly, and in any event not later than thirty (30)
days after its receipt thereof, if it rejects any
Products delivered to it by reason of the failure of
such Products to meet the Specifications. Products not
rejected within such thirty (30) day period shall be
deemed accepted. Lilly shall use reasonable efforts to
replace the rejected Products with Products which meet
the Specifications within the shortest possible time
and shall deliver such replacement Products, at its
sole cost and expense, to Dura. In addition, Lilly
shall, at its sole cost and expense, arrange for all
such noncomplying Products to be picked up promptly in
accordance with all Applicable Laws. Dura shall have
no responsibility to Lilly for the purchase prices of
nonconforming Products but shall pay Lilly the purchase
prices for the replacement Products within 30 days of
delivery thereof.
(b) Notwithstanding subsection (a) above, if Dura and Lilly
disagree on whether any Products comply with the
-7-
Specifications or on the methods for or results of testing
of any of the Products, an independent laboratory which is
acceptable to both parties shall be asked to test the
Products in dispute ("Disputed Products"). To the extent
such laboratory finds that the Disputed Products meet the
Specifications, Dura shall pay the fees of such laboratory
related to such testing and shall promptly pay for the
Disputed Products. To the extent that such laboratory finds
that the Disputed Products fail to meet the Specifications,
Lilly shall pay the fees of such laboratory related to such
testing and shall replace the Disputed Products in
accordance with the preceding subsection (a). Both parties
hereby agree to accept and be bound by the findings of such
independent laboratory.
SECTION 5
REPRESENTATIONS, WARRANTIES AND COVENANTS OF THE PARTIES.
5.1. PRODUCT SPECIFICATIONS AND DELIVERY.
(a) Lilly hereby warrants to Dura that (i) all of the
existing Product inventory and samples purchased by
Dura pursuant to Section 2.1, and (ii) all future Dura
purchases of Products and samples shall, at the date
shipped to Dura, fully conform to the Specifications
and have been manufactured in full compliance with the
Specifications and all Applicable Laws. Lilly further
warrants to Dura that upon delivery of any Products
pursuant hereto, including Lilly's inventory and
samples of the Products contemplated in Section 2.1
hereof, good title to such Products shall convey to
Dura and that such conveyance shall be free and clear
of any security interest, other lien or encumbrance.
(b) Lilly hereby represents and warrants to Dura that it
has the capacity, and subject to the terms and
conditions contained
-8-
herein, will maintain the capacity throughout the term of
this Agreement, to meet the requirements of Dura under this
Agreement.
(c) EXCEPT AS EXPRESSLY PROVIDED IN SECTIONS 5.1(a) AND
(d), LILLY MAKES NO REPRESENTATION OR WARRANTY AS TO
ANY PRODUCTS, EXPRESS OR IMPLIED, EITHER IN FACT OR BY
OPERATION OF LAW, BY STATUTE OR OTHERWISE, AND LILLY
SPECIFICALLY DISCLAIMS ANY AND ALL IMPLIED OR STATUTORY
WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTY
OF MERCHANTABILITY, WARRANTY OF FITNESS FOR A
PARTICULAR PURPOSE OR WARRANTY OF NONINFRINGEMENT.
(d) Nothing contained in this Agreement is intended to
limit or otherwise affect any representation or
warranty provided in the Licensing Agreement.
(e) Lilly hereby covenants that it shall use reasonable
efforts to assure that all of the shipments of Products
ordered by Dura pursuant to a Purchase Order are
shipped timely in accordance with the directions
contained in such Purchase Order.
5.2. INDEMNIFICATION. Indemnification shall be provided under and pursuant
to and in accordance with the terms of Section 8 of the Licensing Agreement,
which terms are by this reference incorporated in and made a part of this
Agreement, and all of which for purposes of this Agreement shall survive any
termination or expiration of the Licensing Agreement.
5.3. NOT DEBARRED. Dura and Lilly each hereby represent and warrant to the
other that it is not debarred and has not and will not knowingly use in any
capacity the services of any person debarred under subsections 306(a) or (b) of
the Generic Drug Enforcement Act of 1992. If at any time this
-9-
representation and warranty is no longer accurate, Dura or Lilly, as the case
may be, shall immediately notify the other of such fact.
SECTION 6
TERM OF AGREEMENT, RENEWAL, TERMINATION
6.1. TERM OF AGREEMENT. Unless sooner terminated in accordance with
this Section 6, this Agreement shall take effect and commence on the Closing
Date and continue in effect for *** which will expire on the date that is
*** from the Closing Date. *** as hereinafter set forth.
6.2. TERMINATION ***
(a) Subject to the provisions of Section 6.6, this Agreement may be
terminated *** with respect to *** at any time after the
*** term of this Agreement without cause upon the occurrence of
*** (i) the giving of at least *** at any time subsequent to the
end of the *** of this Agreement (the *** (ii) *** using
reasonable efforts to *** that quantity of the Product or
Products, as appropriate, *** the end of the *** to meet
anticipated demand therefor *** (the *** The effective date of
the termination of this Agreement shall be the later of the last
day of the *** or the day on which *** In the event of such
termination under this Section 6.2(a), *** shall provide such
reasonable assistance *** as may be reasonably necessary to (x)
obtain any and all *** as may be necessary to enable *** the
Product or Products, as
-10-
--------------------------------------
* CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED BY MEANS OF MARKING
SUCH PORTIONS WITH AN ASTERISK (THE "▇▇▇▇"). THIS EXHIBIT HAS BEEN FILED WITH
THE SECRETARY OF THE COMMISSION WITHOUT THE ▇▇▇▇ PURSUANT TO THE COMPANY'S
APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
appropriate, in the United States (subject to (z) below,
excluding any such *** relating to the *** (y) effect the
transfer of *** for the Product or Products, as appropriate,
*** or a third party *** designated by *** for which *** shall
*** for all of *** reasonable *** in connection therewith, and
(z) enable *** to obtain a reasonable *** necessary for the ***
of the Product or Products, as appropriate, in *** manners: (1)
if on the effective date of the termination of this Agreement ***
is engaged in *** as appropriate, *** to third parties, then ***
shall be required to *** with an amount of *** as appropriate,
equal to the amount of *** as appropriate, purchased by *** (as
reflected by *** as appropriate) under this Agreement in the
previous *** at a price *** as appropriate, *** offered to
similar third parties and as set forth in *** in the *** (2) if
on the effective date of the termination of this Agreement *** is
no longer engaged in *** as appropriate, *** to third parties,
then *** shall be required to *** for the *** is not then ***
which *** shall be used by *** solely for purposes of *** in
accordance with the terms set forth in Section 2.2(b) of the
Licensing Agreement. *** shall *** for all of *** in connection
therewith. Notwithstanding anything contained in clause (z)(2),
above, to the contrary, *** shall not be required to *** required
to *** until on or after ***
-11-
--------------------------------------
* CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED BY MEANS OF MARKING
SUCH PORTIONS WITH AN ASTERISK (THE "▇▇▇▇"). THIS EXHIBIT HAS BEEN FILED WITH
THE SECRETARY OF THE COMMISSION WITHOUT THE ▇▇▇▇ PURSUANT TO THE COMPANY'S
APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
*** unless *** agrees to *** solely *** reasonably approved by
*** provided, however, that should *** desire to *** from third
parties, *** shall *** for all *** invoiced prior to *** in an
amount *** from a third party and *** for such *** in the prior
*** provided further, however, that *** shall not be required to
*** for any *** during this period *** as provided pursuant to
the Requirements Document. The termination by *** of this
Agreement with respect to *** as set forth in this Section 6.2(a)
shall not in any way *** pursuant to the terms set forth herein
and in Sections 2.2(a) and (b) of the Licensing Agreement.
(b) Subject to the provisions of Section 6.6, this Agreement may be
terminated by *** with respect to *** if *** fails to *** at
least *** and *** in any *** Such termination shall not be
effective until *** has provided *** with written notice thereof.
The termination by *** of this Agreement with respect to *** as
set forth in this Section 6.2(b) shall not in any way ***
pursuant to the terms set forth herein and in Section 2.2(a) of
the Licensing Agreement.
-12-
--------------------------------------
* CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED BY MEANS OF MARKING
SUCH PORTIONS WITH AN ASTERISK (THE "▇▇▇▇"). THIS EXHIBIT HAS BEEN FILED WITH
THE SECRETARY OF THE COMMISSION WITHOUT THE ▇▇▇▇ PURSUANT TO THE COMPANY'S
APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
6.3. TERMINATION BY ***. Subject to the provisions of Section 6.6, this
Agreement may be terminated by *** with respect to *** at any time after the ***
of this Agreement *** upon the giving of *** to *** (the *** and the effective
date of the termination of this Agreement shall be the date specified in the ***
Upon receipt of *** shall, without delay, *** as appropriate and as permitted,
all matters affected by or resulting from *** but *** and *** shall *** under
this Agreement in accordance with the terms thereof. In the event of such
termination, *** shall provide such reasonable *** as may be reasonably
necessary to *** as appropriate, from *** or a third party *** and *** shall
*** all of *** reasonable *** in connection therewith. The termination by ***
of this Agreement with respect to *** shall not in any way limit *** pursuant to
the terms set forth in Section 2.2(a) of the Licensing Agreement.
6.4. TERMINATION FOR INSOLVENCY. If either Dura or Lilly (i) makes a
general assignment for the benefit of creditors or becomes insolvent; (ii) files
an insolvency petition in bankruptcy; (iii) petitions for or acquiesces in the
appointment of any receiver, trustee or similar officer to liquidate or conserve
its business or any substantial part of its assets; (iv) commences under the
laws of any jurisdiction any proceeding involving its insolvency, bankruptcy,
reorganization, adjustment of debt, dissolution, liquidation or any other
similar proceeding for the release of financially distressed debtors; or (v)
becomes a party to any proceeding or action of the type described above in (iii)
or (iv) and such proceeding or action remains undismissed or unstayed for a
period of more than sixty (60) days, then the other party may by written notice
terminate this Agreement in its entirety with immediate effect.
-13-
--------------------------------------
* CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED BY MEANS OF MARKING
SUCH PORTIONS WITH AN ASTERISK (THE "▇▇▇▇"). THIS EXHIBIT HAS BEEN FILED WITH
THE SECRETARY OF THE COMMISSION WITHOUT THE ▇▇▇▇ PURSUANT TO THE COMPANY'S
APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
6.5. TERMINATION FOR DEFAULT.
(a) Dura and Lilly shall each have the right to terminate
this Agreement with respect to a specific Product for
default upon the other's failure to comply in any
material respect with the terms and conditions of this
Agreement that relate to such specific Product. At
least ninety (90) days prior to any such termination
for default the party seeking to so terminate shall
give the other written notice of its intention to
terminate this Agreement in accordance with the
provisions of this Section 6.5, which notice shall set
forth the default(s) which form the basis for such
termination. If the defaulting party fails to correct
such default(s) within ninety (90) days after the
receipt of notification, or if the same reasonably
cannot be corrected or remedied within ninety (90)
days, then if the defaulting party has not commenced
curing said default(s) within said ninety (90) days and
be diligently pursuing completion of same, then such
party immediately may terminate this Agreement with
respect to such Product. In addition, any default by a
party under the Licensing Agreement shall be deemed to
be a default by such party hereunder.
(b) This Section 6.5 shall not be exclusive and shall not
be in lieu of any other remedies available to a party
hereto for any default hereunder on the part of the
other party.
(c) Notwithstanding anything herein to the contrary, if
*** terminates this Agreement pursuant to Section 6.5(a),
then *** shall be required to (x) *** as may be necessary to
enable *** the *** as appropriate, *** and (y) effect the
*** for the ***
-14-
--------------------------------------
* CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED BY MEANS OF MARKING
SUCH PORTIONS WITH AN ASTERISK (THE "▇▇▇▇"). THIS EXHIBIT HAS BEEN FILED WITH
THE SECRETARY OF THE COMMISSION WITHOUT THE ▇▇▇▇ PURSUANT TO THE COMPANY'S
APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
*** as appropriate, from *** to *** or a third party ***
designated by *** for which *** shall *** for all of *** in
connection therewith. Notwithstanding anything contained in
clause (y), above, to the contrary, *** shall not be required to
*** required to *** until on or after *** unless *** agrees to
*** solely *** in a *** reasonably *** provided, however, that
should *** desire to *** shall *** for *** invoiced prior to ***
in an amount *** third party *** in the *** provided further,
however, that *** shall not be required to *** for any *** during
this period in *** of the *** reflected in *** as provided
pursuant to the Requirements Document.
6.6. CONTINUING OBLIGATIONS. Termination of this Agreement for any
reason shall not relieve the parties of any obligation accruing prior thereto
with respect to the terminated Product and any ongoing obligations hereunder
with respect to the remaining Product and shall be without prejudice to the
rights and remedies of either party with respect to any antecedent breach of the
provisions of this Agreement. Without limiting the generality of the foregoing,
no termination of this Agreement, whether by lapse of time or otherwise, shall
serve to terminate the obligations of the parties hereto under subsections 2.3,
2.4, 2.5, 2.6, 3.2, 3.3, 3.4, 4.3, 5.1, 5.2, 6.2, 6.5, 6.6, and 6.7, section 7,
section 8 (except for subsection 8.14, which shall expire as described therein)
hereof, and such obligations shall survive any such termination.
-15-
--------------------------------------
* CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED BY MEANS OF MARKING
SUCH PORTIONS WITH AN ASTERISK (THE "▇▇▇▇"). THIS EXHIBIT HAS BEEN FILED WITH
THE SECRETARY OF THE COMMISSION WITHOUT THE ▇▇▇▇ PURSUANT TO THE COMPANY'S
APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
6.7. RETURNED MATERIALS. On the termination of this Agreement, Lilly and
Dura each shall return to the other all information which it possesses or
controls that belongs to the other, except that each may retain a copy for
recordkeeping purposes.
SECTION 7
RESTRICTIVE COVENANTS
7.1. NON-COMPETE. For and during the period *** and, if *** pursuant to
*** for the period ending on the *** (the *** neither *** shall, directly or
indirectly, *** on (unless such *** are *** or *** an *** provided, however,
that nothing set forth herein shall prevent *** from (a) *** (b) *** or (c)
subject to the following sentence, *** which at the time of *** Notwithstanding
the above, *** acknowledges and agrees that the following activities, events and
conditions *** of this Section 7.1 and *** in any *** or *** of any nature
whatsoever (each, a *** in which the other *** in such *** (each, the *** at
that time already conducts or engages in, directly or indirectly, anywhere ***
the *** (the *** provided that the *** (i) *** a *** of the *** of the ***
-16-
--------------------------------------
* CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED BY MEANS OF MARKING
SUCH PORTIONS WITH AN ASTERISK (THE "▇▇▇▇"). THIS EXHIBIT HAS BEEN FILED WITH
THE SECRETARY OF THE COMMISSION WITHOUT THE ▇▇▇▇ PURSUANT TO THE COMPANY'S
APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
*** prior to the *** (ii) will not constitute a *** of the *** of either *** or
*** as the case may be, following *** and (iii) would not have a *** Further, no
provision herein contained shall *** in any fashion *** to conduct or engage in
***
7.2. CONFIDENTIALITY. Confidentiality of information shall be provided
under and pursuant to and in accordance with the terms of Section 7.5 of the
Licensing Agreement, which terms are by this reference incorporated in and made
a part of this Agreement, and all of which for purposes of this Agreement shall
survive any termination or expiration of the Licensing Agreement.
SECTION 8
MISCELLANEOUS PROVISIONS
8.1. SUCCESSORS AND ASSIGNS. This Agreement shall be binding upon and
shall inure to the benefit of the parties hereto and their respective successors
and assigns; PROVIDED, HOWEVER, that neither Lilly nor Dura may assign any of
its rights, duties or obligations hereunder without the prior written consent of
the other, which consent may be withheld in the other's sole discretion, except
that no prior written consent shall be required (i) in the event that a third
party acquires substantially all of the assets or outstanding shares of, or
merges with, Dura or Lilly, as the case may be, or (ii) in the event Lilly
assigns any or all of its obligations hereunder to an Affiliate of Lilly or a
third party but only so long as Lilly agrees to be bound by all of its
responsibilities and obligations hereunder. No assignment of this Agreement or
of any rights hereunder shall relieve the assigning party of any of its
obligations or liability hereunder.
8.2. NOTICES. All notices or other communications required or permitted to
be given hereunder shall be in writing and shall be deemed to have been duly
given if delivered by hand, prepaid telex, cable, telegram or facsimile and
confirmed in writing, or mailed first class, postage prepaid, by
-17-
--------------------------------------
* CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED BY MEANS OF MARKING
SUCH PORTIONS WITH AN ASTERISK (THE "▇▇▇▇"). THIS EXHIBIT HAS BEEN FILED WITH
THE SECRETARY OF THE COMMISSION WITHOUT THE ▇▇▇▇ PURSUANT TO THE COMPANY'S
APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
registered or certified mail, return receipt requested (mailed notices and
notices sent by telex, cable or telegram shall be deemed to have been given on
the date received) as follows:
If to Lilly, as follows:
▇▇▇ ▇▇▇▇▇ and Company
Lilly ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇▇▇▇▇
Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇
Attn: President, North American Pharmaceutical Operations
With a copy to:
▇▇▇ ▇▇▇▇▇ and Company
Lilly ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇
▇▇▇▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇▇▇▇▇
Facsimile: (▇▇▇) ▇▇▇-▇▇▇▇
Attn: General Counsel
If to Dura, as follows:
Dura Pharmaceuticals, Inc.
▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇-▇▇▇▇
Attn: Office of the General Counsel
or in any case to such other address or addresses as hereafter shall be
furnished as provided in this Section 8.2 by any party hereto to the other
party.
8.3. WAIVER; REMEDIES. No delay on the part of Lilly or Dura in exercising
any right, power or privilege hereunder shall operate as a waiver thereof, nor
shall any waiver on the part of either Lilly or Dura of any right, power or
privilege hereunder operate as a waiver of any other right, power or privilege
hereunder nor shall any single or partial exercise of any right, power or
privilege hereunder preclude any other or further exercise thereof or the
exercise of any other right, power or privilege hereunder. The indemnification
provided in Section 8 of the Licensing Agreement shall be the sole remedy
available for any Damages arising out of or in connection with this Agreement
except for any rights or remedies which the parties hereto may otherwise have in
equity.
-18-
8.4. ENTIRE AGREEMENT. This Agreement (together with the Licensing
Agreement) and its appendices constitute the entire agreement between the
parties with respect to the subject matter hereof and supersede all prior
agreements or understandings of the parties relating thereto.
8.5. AMENDMENT. This Agreement may be modified or amended only by written
agreement of the parties hereto.
8.6. COUNTERPARTS. This Agreement may be executed in any number of
counterparts, each of which shall be deemed an original but all of which
together shall constitute a single instrument.
8.7. GOVERNING LAW. This Agreement shall be governed and construed in
accordance with the laws of the State of Indiana excluding any choice of law
rules which may direct the application of the law of another state.
8.8. CAPTIONS. All section titles or captions contained in this Agreement
and in any appendix referred to herein or annexed to this Agreement are for
convenience only, shall not be deemed a part of this Agreement and shall not
affect the meaning or interpretation of this Agreement.
8.9. NO THIRD-PARTY RIGHTS. No provision of this Agreement shall be deemed
or construed in any way to result in the creation of any rights or obligation in
any Person not a party to this Agreement.
8.10. CONSTRUCTION. This Agreement shall be deemed to have been drafted by
both Lilly and Dura and shall not be construed against either party as the
draftsperson hereof.
8.11. APPENDICES. Each Appendix hereto is incorporated by reference and
made a part of this Agreement.
8.12. NO JOINT VENTURE. Nothing contained herein shall be deemed to create
any joint venture or partnership between the parties hereto, and, except
-19-
as is expressly set forth herein, neither party shall have any right by virtue
of this Agreement to bind the other party in any manner whatsoever.
8.13. SEVERABILITY. If any provision of this Agreement is held to be
illegal, invalid, or unenforceable under present or future laws effective while
this Agreement remains in effect, the legality, validity and enforceability of
the remaining provisions shall not be affected thereby.
8.14. FORCE MAJEURE. If either party is prevented from complying, either
totally or in part, with any of the terms or provisions set forth herein with
respect to either one or both of the Products by reason of force majeure,
including, by way of example and not of limitation, fire, flood, explosion,
storm, strike, lockout or other labor dispute, riot, war, rebellion, accidents,
acts of God, acts of governmental agencies or instrumentalities, failure of
suppliers or any other cause or externally induced casualty beyond its
reasonable control, whether similar to the foregoing contingencies or not, said
party shall provide written notice of same to the other party. Said notice
shall be provided within five (5) working days of the occurrence of such event
and shall identify the requirements of this Agreement or such of its obligations
as may be affected, and to the extent so affected, said obligations shall be
suspended during the period of such disability. If any raw materials, facility
systems or capacity is used for both the affected Product and any other products
or purposes, any necessary allocation shall be made as between Lilly's needs
(including those of any Affiliate of Lilly), Dura's needs and the needs of any
other party to whom Lilly has firm contractual obligations on a basis no less
favorable than pro rata on a volume basis. The party prevented from performing
hereunder shall use reasonable efforts to remove such disability, and shall
continue performance whenever such causes are removed. The party so affected
shall give to the other party a good faith estimate of the continuing effect of
the force majeure condition and the duration of the affected party's
nonperformance. If the period of any previous actual nonperformance of Lilly
because of Lilly force majeure conditions plus the anticipated future period of
Lilly nonperformance because of such conditions will exceed an aggregate of two
hundred seventy (270) days within any twenty-four (24) month period, Dura may
terminate this Agreement by notice to Lilly. If the period of any previous
actual nonperformance of Dura
-20-
because of Dura force majeure conditions plus the anticipated future period of
Dura nonperformance because of such conditions will exceed an aggregate of two
hundred seventy (270) days within any twenty-four (24) month period, Lilly may
terminate this Agreement by notice to Dura. When such circumstances as those
contemplated herein arise, the parties shall discuss in good faith, what, if
any, modification of the terms set forth herein may be required in order to
arrive at an equitable solution.
[End of text]
-21-
IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of
the date first above written.
▇▇▇ ▇▇▇▇▇ AND COMPANY
By: /s/ ▇▇▇▇▇▇ ▇▇▇▇▇▇
Title: President and Chief Operating
Officer
DURA PHARMACEUTICALS, INC.
By: /s/ Cam ▇. ▇▇▇▇▇▇
Title: Chairman, President and
Chief Executive Officer
Dura/Manufacturing Agreement-8/20/96
-22-
MANUFACTURING AGREEMENT
EXHIBIT A
PRODUCTS
PRODUCT CONTAINER FULL LOT MANUFACTURING/ LILLY NDA NO.
TITLES COUNT/SIZE QUANTITIES PACKAGING PRODUCT
SITE ITEM CODE
--------------------------------------------------------------------------------------------------------------------
Ceclor CD Bottles of 60 12,670 Lilly Industries TA4220 50-673
375mg Carolina, PR
PR03
--------------------------------------------------------------------------------------------------------------------
Ceclor CD Blister of 4 142,500 Lilly Dry Products TA4221 50-673
500mg (sample) ▇▇▇▇▇▇▇▇▇▇▇▇, ▇▇
▇▇▇▇ ▇▇▇
--------------------------------------------------------------------------------------------------------------------
Ceclor CD Bottles of 60 9,500 Lilly Industries TA4221 50-673
500mg Carolina, PR
PR03
--------------------------------------------------------------------------------------------------------------------
Keftab Blister of 4 **** Lilly Dry Products TA4143 50-614
500mg (sample) Indianapolis, IN
Bldg 328
--------------------------------------------------------------------------------------------------------------------
Keftab Bottles of 5,640 Lilly Industries TA4143 50-614
500mg 100 Carolina, PR
PR03
--------------------------------------------------------------------------------------------------------------------
--------------------------------------
* CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED BY MEANS OF MARKING
SUCH PORTIONS WITH AN ASTERISK (THE "▇▇▇▇"). THIS EXHIBIT HAS BEEN FILED WITH
THE SECRETARY OF THE COMMISSION WITHOUT THE ▇▇▇▇ PURSUANT TO THE COMPANY'S
APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
EXHIBIT B
EXISTING INVENTORY AND SAMPLES
SAMPLES
1. *** shall *** an aggregate of (a) *** Samples of Keftab (500 mg 2 x 2
Samples), and (b) *** Samples of Ceclor CD (*** x 2 Samples).
2. Subject to the provisions set forth in Section 4 of the Requirements
Document, *** with the following initial quantities of samples: (a)
*** sample units of Keftab, and (b) *** sample units of Ceclor CD. These
samples shall be *** consistent with No. 1 above.
3. *** sample units of Ceclor CD at a purchase price equal to *** per sample
unit. Lilly shall invoice Dura for Dura's purchase of these samples in
accordance with the provisions contained in the Manufacturing Agreement.
4. Dura shall designate on any Purchase Order for samples: (a) the amount of
Keftab and/or Ceclor CD samples, as appropriate, which are to be *** and
(b) the amount of Keftab and/or Ceclor CD samples, as appropriate, which
are to be *** in accordance under this Agreement.
5. In no event shall *** aggregate samples of Keftab and *** aggregate samples
of Ceclor CD hereunder.
INVENTORY
1. ***
(a) that quantity of Keftab trade bottles equal to (i) the *** bottles of
inventory as of *** less (ii) the number of bottles *** at a purchase
price equal to *** per bottle; and
(b) *** bottles of Ceclor CD *** tablets and *** bottles of Ceclor CD ***
tablets at a purchase price equal to *** per bottle and
*** per bottle, respectively.
2. Lilly shall invoice Dura for Dura's purchase of the above Products in
accordance with the provisions contained in the Manufacturing Agreement.
-2-
--------------------------------------
* CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED BY MEANS OF MARKING
SUCH PORTIONS WITH AN ASTERISK (THE "▇▇▇▇"). THIS EXHIBIT HAS BEEN FILED WITH
THE SECRETARY OF THE COMMISSION WITHOUT THE ▇▇▇▇ PURSUANT TO THE COMPANY'S
APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
3
EXHIBIT C
PRICES OF PRODUCTS AND SAMPLES
(a) *** will be invoiced at the following prices:
Product Price
------- -----
Ceclor CD
*** Bottles of 60 Tablets ***
*** Bottles of 60 Tablets ***
Keftab
500 mg Bottles of 100 Tablets ***
(b) *** will be invoiced at the following prices:
Keftab 500 mg 2 x 2 Samples *** per Sample
Ceclor CD *** 2 x 2 Samples *** per Sample
(c) Beginning *** and on *** shall *** the *** in *** for such presentations
(determined in accordance with *** consistently applied), but in no case
*** for any Product (including samples of Product) *** shall give ***
notice on or before *** of any and all *** with said *** to be effective
*** received after *** of the ***
(d) Any modifications or adjustments to any of the prices set forth on this
Exhibit C for reasons other than those described in paragraph (c), above,
shall be evidenced in writing and be executed by an authorized
representative of each party.
--------------------------------------
* CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED BY MEANS OF MARKING
SUCH PORTIONS WITH AN ASTERISK (THE "▇▇▇▇"). THIS EXHIBIT HAS BEEN FILED WITH
THE SECRETARY OF THE COMMISSION WITHOUT THE ▇▇▇▇ PURSUANT TO THE COMPANY'S
APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
APPENDIX A
LILLY * DURA
MANUFACTURING
REQUIREMENTS
DOCUMENT
CECLOR-Registered Trademark- CD AND KEFTAB-Registered Trademark-
PRODUCTS
(Revision No. O, , 1996)
---
SECTION 1
INTRODUCTION
1.0. This Manufacturing Requirements Document ("MRD") describes certain
procedures, personnel contacts and other matters relating to the manufacturing
and supplying of Products by Lilly to Dura. Capitalized terms used in this MRD
and not otherwise defined herein shall have the meanings ascribed to such terms
in the Manufacturing Agreement to which this MRD is attached as Appendix A. The
Products covered by this document are listed in ATTACHMENT I.
Throughout this document, references are made to individuals from Dura and
Lilly by title. Refer to the Key Contacts list, ATTACHMENT II, to obtain the
name and phone number of the individual.
SECTION 2
ADMINISTRATION
2.0. Revisions shall be coordinated by one Lilly employee and one Dura
employee. These two individuals will have responsibility for alerting any
affected persons within their respective companies and for coordinating any
required implementation.
Each change in this MRD may be made only by the designated representatives
set forth below and will cause a change in the revision number reflected on the
cover page of this document. Lilly will maintain the master copy and make the
agreed upon changes. A new revision will then be sent to Dura. The designated
Dura representative will acknowledge receipt and acceptance of such new revision
by sending a memo to the designated Lilly representative. The designated
representatives are:
Lilly: ▇▇▇▇▇ ▇▇▇▇▇
Dura: ▇▇▇▇ ▇▇▇▇▇▇▇
Either company may change its designated representative by giving notice
thereof to the other in accordance with the provisions of the Manufacturing
Agreement. These contacts from Lilly and Dura will be the primary contacts for
any questions or requests that either party might have with this MRD or the
Products.
SECTION 3
QUALITY ASSURANCE/REGULATORY REQUIREMENTS
3.1. INCOMING COMPONENT INSPECTIONS. Lilly has and will maintain standard
operating procedures ("SOPs") for inspections of all components used in the
manufacture of the Products. Incoming raw material, actives, and components as
well as finished goods are included in the inspection program. Inspections shall
be conducted in accordance with approved/validated methods and Specifications.
Documentation of all inspections shall be maintained per procedure. Access to
Lilly's SOPs shall be made available by Lilly to Dura upon Dura's reasonable
request.
3.2. ANNUAL REVIEWS. Lilly will perform annual Product quality reviews for
all Products produced at its manufacturing sites. An annual Product quality
review report will be created for each calendar year, including information
concerning batches produced, complaints, rejections, investigations, recalls,
quality, analytical, microbiological and stability data as applicable. Access
to such reports shall be made available by Lilly to Dura upon Dura's reasonable
request.
3.3. STABILITY. Lilly will perform stability testing required to support
the NDAs and ongoing commercial stability monitoring of the Products. Stability
testing and monitoring will be conducted following Lilly-approved protocols in
the approved NDAs.
3.4. BATCH DOCUMENTATION & QUALITY RECORDS. Lilly will maintain original
batch documentation in a secure Lilly facility for a period of three (3) years
after the expiry of the expiration dating of the applicable Products. All
documentation is and will be reviewed by Lilly Quality Control for adherence to
internal procedures, GMPs and the approved NDAs.
-2-
After any Product release, a Certificate of Analysis will be sent by
overnight mail or by telecopy (receipt confirmed) to arrive at Dura prior to
such Product's delivery, addressed to Attention: Quality Assurance.
A copy of the MSDS documents are included as ATTACHMENT III to this
document.
3.5. RESERVE SAMPLES. Lilly will maintain reserve samples to comply with
the Code of Federal Regulations 21 CFR 211.170 for the Products. Samples from
Product lots tested for release at Lilly facilities will be maintained in a
secure Lilly storage facility consistent with the storage conditions for the
Products.
3.6. MATERIAL CONTROL. Control and traceability of all materials used in
the manufacture of the Products will be accomplished by adherence to internal
SOPs.
3.7. NON-CONFORMING OR REJECTED MATERIAL. In process and finished
Products considered unacceptable by Lilly Quality Control will be rejected by
Lilly Quality Control in accordance with internal SOPs which have been
established and will be maintained by Lilly. These Products will be identified
as unsuitable for use and segregated from approved material with the appropriate
investigation reports and labeling pursuant to such SOPs.
3.8. DESTROY ORDER SYSTEM. There is a formal system, which has been
established and will be maintained by Lilly, by which obsolete material is
destroyed and the destruction documented. Access to destruction documentation
related to Products shall be made available by Lilly to Dura upon Dura's
request. Material for which Dura is financially responsible will not be
destroyed until at least ten (10) days after Lilly has provided notice of the
proposed destruction to the designated Key Contact from Dura.
3.9. LABORATORY ANALYSIS. Lilly will test Products using
approved/validated methods and Specifications according to the approved NDAs.
There is a procedure in place, which Lilly will maintain, for investigation and
disposition of out-of-Specifications or abnormal testing results.
-3-
3.10. TRAINING/QUALIFICATION. Lilly has and will maintain a program to
assure that all personnel engaged in the manufacturing, filling, packaging, and
shipping of Products have the education, training and/or experience required to
properly perform their assigned functions in compliance with GMPs. Training of
all personnel is and shall be documented by Lilly.
3.11. DEVIATIONS. Lilly has and will maintain formal procedures for
notifying appropriate Lilly personnel, including management, and performing
investigations in connection with deviations relating to the manufacture,
processing, packaging, testing or storage of the Products. These procedures
define the criteria and process by which all deviations relating to the
manufacture, processing, packaging, labeling, testing or storage of the
Products, including those which may affect safety, identity, strength, efficacy,
quality or purity, are to be evaluated, justified, documented and approved.
3.12. REGULATORY REQUIREMENTS. Dura and Lilly have jointly developed
written procedures for (i) the reporting of adverse drug experiences, as set
forth on EXHIBIT D to the Licensing Agreement, (ii) the submission by Dura to
Lilly and by Lilly to FDA of labeling and promotional materials related to the
Products as set forth in EXHIBIT E to the Licensing Agreement, (iii)
administration of and response to medical inquiries concerning the Products by
consumers, physicians, pharmacists and other health care professionals as set
forth in EXHIBIT F to the Licensing Agreement, and (iv) administration and
analysis of and response to complaints concerning the Products as set forth in
EXHIBIT G to the Licensing Agreement. Dura and Lilly shall each comply with
the provisions thereof.
SECTION 4
INVENTORY POLICY & MATERIAL PLANNING
4.0. Lilly's and Dura's goals include a continuing effort to reduce cycle
time through the plant and through material and component acquisition to
minimize inventory while responding fully to market demand. Attainment of this
goal requires well developed channels of communication. This benefits both
parties by reducing the investment in inventory. Because of the process flow
inherent in the Products at the plant, schedule changes require advance
planning.
-4-
- Dura agrees that it cannot submit a purchase order hereunder for Keftab
samples in excess of the quantity thereof set forth on Exhibit B to the
Manufacturing Agreement unless such purchase order is submitted to Lilly in
accordance with the terms set forth herein before the close of business on
Friday, August 23, 1996. Dura further agrees and acknowledges that Lilly
shall not be required to begin to process any purchase order pursuant to
the terms set forth herein for any additional quantities of Keftab samples
until after November 15, 1996.
- Dura agrees that it cannot submit a purchase order hereunder for Ceclor CD
samples in excess of the quantity set forth on Exhibit B to the
Manufacturing Agreement unless such purchase order is submitted to Lilly in
accordance with the terms set forth herein before the close of business on
Friday, August 23, 1996. Dura further agrees and acknowledges that Lilly
shall not be required to begin to process any purchase order pursuant to
the terms set forth herein for any additional quantities of Ceclor CD
samples until after April 15, 1997; provided, however, that if Dura has
submitted a purchase order in accordance with the terms set forth herein by
the close of business on April 15, 1997, then Lilly shall deliver no more
than one lot of Ceclor CD samples to Dura on or before June 15, 1997;
provided further that any additional quantities of Ceclor CD samples shall
be provided by Lilly to Dura in accordance with the terms set forth herein.
- On or before the 15th of each month, Dura shall provide Lilly with a
rolling forecast (the "Forecast"), for which no binding purchase order
exists, of its estimated requirements for each of the Products (including,
without limitation, samples thereof) for each of the next five (5)
quarters. In addition, in December of each year Dura shall provide Lilly
with a non-binding forecast of its estimated requirements for each of the
Products (including, without limitation, samples thereof) for the next
thirty-six (36) months.
- Reasonable quantities of unique components, or materials that are not used
in the manufacture of Lilly's other products, will be purchased by Lilly in
reliance by Lilly on Dura's Forecast of its estimated
-5-
requirements. If Dura thereafter requests any change that causes any
obsolescence of any such unique components or materials purchased by Lilly,
Dura shall be responsible to Lilly for the costs associated with said
components or materials (including, but not limited to, any costs related
to the destruction of such components or materials).
- Dura shall purchase not less than 80% of the quantities identified in its
most recent applicable quarterly Forecast and Lilly shall not be obligated
to provide more than 120% of such quantities. An example of the foregoing
is set forth in ATTACHMENT IV hereto.
- Purchase Orders will be issued from Dura to Lilly at least ninety (90) days
prior to the delivery date specified in each Purchase Order. All Purchase
Orders shall be for full lot quantities (as set forth on ATTACHMENT I
hereto); delivery of greater than 90% of the quantity ordered shall be
accepted by Dura in full satisfaction of the quantity ordered in such
Purchase Order.
- Lead times on copy code changes (not reprints of approved labeling) from
receipt of Dura's approval of the proposed copy code shall be:
Labels 8 weeks
Literature 8 weeks
Cartons 9 weeks
Shipping Cases 4 weeks
- Lead time for product packaging is in addition to the lead time set forth
for the above-described copy code changes.
-6-
SECTION 5
SHIPMENT OF FINISHED GOODS
5.0. A copy of the ▇▇▇▇ of lading will be included as shipping paperwork
with each order.
Dura will select and pay the carrier to be used. These Products will be
shipped F.O.B. shipping point, freight class, Class 70 (Class of Commodity for
Food and Pharmaceutical Products) or as may otherwise be required pursuant to
Applicable Laws.
Should Dura request Lilly to warehouse any Product, Lilly will use
reasonable efforts to comply, and Dura shall pay to Lilly a warehousing fee per
pallet per day of Two Dollars Fifty Cents ($2.50).
Any discrepancies between quantity shipped from Lilly and quantity arriving
at Dura shall be jointly investigated.
SECTION 6
PACKAGE DESIGN
6.0. Initial package design for Product samples and trade shall be
provided by Lilly.
This procedure encompasses all changes in the design of packaging (see
section titled "Control of Printed Material" for graphic changes):
- Lilly will assign a unique item number for each packaging component
and a detailed specification.
- Dura will supply label designs to Lilly for artwork creation and
ordering of package components.
- Lilly requires a unique pharmacode on each primary label. This
assignment will be contained in the detailed specification. The
pharmacode is intended to be scanned at the printing supplier and on
-7-
the packaging lines to ensure that the correct label is being used.
The pharmacode will be put in position by Lilly.
- In general, minor changes to secondary packaging may be made without
the review process if the change is considered to be functionally
equivalent or unnoticed by the end user. An example might be a change
in paper weight or fold in the prescribing information to improve
packaging efficiency (assuming no corresponding graphic change is
required in a fold change). Specifications and component sheets will
be revised, as appropriate.
SECTION 7
ADDRESSES
7.0. Purchase Orders should be placed and forecasts sent as follows:
Orders and forecasts should be mailed to:
▇▇▇ ▇▇▇▇▇ Industries, Inc.
Call ▇▇▇ ▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇-▇▇▇▇
Attn: Customer Services, PR03
and a copy of any forecast should be mailed to:
▇▇▇ Lilly and Company
▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇
Drop Code 4028
Attn: Inventory Planner
▇▇▇▇▇▇▇▇▇▇▇▇, ▇▇ ▇▇▇▇▇
At the time the Purchase Order is mailed, a copy should be faxed to Lilly
Customer Service Representative, FAX (▇▇▇)▇▇▇-▇▇▇▇.
Once Products are shipped, Lilly will invoice Dura. Invoice will reference
Dura Purchase Order, quantity, description, price, and shipping document number.
-8-
Invoices will be mailed to:
Dura Pharmaceuticals, Inc.
▇▇▇▇ ▇▇▇▇▇▇▇ ▇▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇
▇▇▇ ▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇-▇▇▇▇
Attn: Finance Department
SECTION 8
CONTROL OF PRINTED MATERIAL
8.0. Dura will supply label designs to Lilly. Lilly will prepare final
artwork and printer's proofs for initial approval by: Lilly's Regulatory Affairs
Group, CM&C Regulatory Group, and Printed Package Materials Groups, and by
Dura's Regulatory/Medical Affairs/Marketing Group. Lilly will then forward
these proofs to the attention of Dura's Vice President of Regulatory Affairs.
Following receipt of proof approval from Dura, Lilly will have labeling
components printed in accordance with SOPs for graphics preparation and
processing printing orders.
Any revisions to approved labeling will be requested by Dura to Lilly's
Regulatory Affairs Group. Lilly will prepare final artwork and printer's proofs
for approval by: Lilly's Regulatory Affairs Group, CM&C Regulatory Group, and
Printed Package Materials Groups and by Dura's Regulatory/Medical
Affairs/Marketing Group. Lilly will then forward these proofs to the attention
of Dura's Vice President of Regulatory Affairs. Following receipt of proof
approval from Dura, Lilly will have labeling components printed in accordance
with SOPs for graphics preparation and processing printing orders. Dura
approval shall not be required for reprints of currently approved labeling with
no revisions.
SECTION 9
PROCESS CHANGE AND VALIDATION
9.0. Lilly has and will maintain procedures that help it determine if
process changes are occurring and guide it in administering process changes.
The current Product Specifications are included in ATTACHMENT V. If Dura
requests a change in Specifications, packaging, process or any other matters
-9-
covered by this MRD, Lilly will determine the steps necessary and the costs
associated to accomplish the change and will communicate that information to
Dura. Upon Dura's acceptance of responsibility for the costs of such change and
such other conditions as may be reasonably necessary for Lilly to accomplish the
change (including lead time), Lilly will make such change. If Lilly desires any
such change, it shall follow a reciprocal procedure with Dura. If, in Lilly's
reasonable belief, any process change would result in a material change in a
Product's appearance, lot size (whether trade or sample), or inventory level,
Lilly shall provide Dura with at least ten (10) business days notice before
implementing such change.
Whenever this MRD refers to "Standard operating procedures" or "SOPs" or
"programs" that Lilly "has and will maintain", such phrases or phrases of
similar import shall be deemed to mean that Lilly shall, throughout the term of
the Manufacturing Agreement, have and maintain the referenced procedures or
programs as they may be modified from time to time in Lilly's discretion without
the need for notice to, or the consent of, Dura; provided, however, that Lilly
shall upon Dura's reasonable request make such procedures or programs, as so
modified, available for review by Dura.
SECTION 10
PRICING
10.0. Products shall be purchased by Dura from Lilly pursuant to the terms
and conditions set forth in Section 2 of the Manufacturing Agreement and at the
prices set forth on Exhibit C thereto (a copy of which is attached hereto as
ATTACHMENT VI). If any prices are adjusted pursuant to the terms contained in
Exhibit C, then such revised exhibit shall be attached hereto as a revised
ATTACHMENT VI.
-10-
ATTACHMENT I
PRODUCTS
PRODUCT CONTAINER FULL LOT MANUFACTURING/ LILLY NDA NO.
TITLES COUNT/SIZE QUANTITIES PACKAGING PRODUCT
SITE ITEM CODE
--------------------------------------------------------------------------------
Ceclor CD Bottles of 12,670 Lilly Industries TA4220 50-673
375mg 60 Carolina, PR
PR03
--------------------------------------------------------------------------------
Ceclor CD Blister of 4 142,500 Lilly Dry Products TA4221 50-673
500mg (sample) ▇▇▇▇▇▇▇▇▇▇▇▇, ▇▇
▇▇▇▇ ▇▇▇
--------------------------------------------------------------------------------
Ceclor CD Bottles of 9,500 Lilly Industries TA4221 50-673
500mg 60 Carolina, PR
PR03
--------------------------------------------------------------------------------
Keftab Blister of 4 **** Lilly Dry Products TA4143 50-614
500mg (sample) Indianapolis, IN
Bldg 328
--------------------------------------------------------------------------------
Keftab Bottles of 5,640 Lilly Industries TA4143 50-614
500mg 100 Carolina, PR
PR03
--------------------------------------------------------------------------------
--------------------------------------
* CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED BY MEANS OF MARKING
SUCH PORTIONS WITH AN ASTERISK (THE "▇▇▇▇"). THIS EXHIBIT HAS BEEN FILED WITH
THE SECRETARY OF THE COMMISSION WITHOUT THE ▇▇▇▇ PURSUANT TO THE COMPANY'S
APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
ATTACHMENT II
KEY CONTACT LIST
NAME TITLE ROLE DEPT. LOCATION TELEPHONE MAIL FAX NUMBER
DROP CODE
---------------------------------------------------------------------------------------------------------------------------------
LILLY PUERTO RICO
*** *** *** 41J PR03 *** PR03 ***
*** *** *** 50J PR03 *** PR03 ***
*** *** *** 72J PR03 *** PR03 ***
*** *** *** 72J PR03 *** PR03 ***
*** *** *** 72J PR03 *** PR03 ***
*** *** *** 43J PR03 *** PR03 ***
*** *** *** 73J PR03 *** PR03 ***
*** *** *** 43J PR03 *** PR03 ***
*** *** *** 50J PR03 *** PR03 ***
LILLY INDIANAPOLIS
*** *** *** IC241 170/01 *** 4112 ***
*** *** *** MC327 74/10 *** 1102 ***
*** *** *** MC675 15/4 *** 2543 ***
*** *** *** MC216 74/5 *** 1056 ***
--------------------------------------
* CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED BY MEANS OF MARKING
SUCH PORTIONS WITH AN ASTERISK (THE "▇▇▇▇"). THIS EXHIBIT HAS BEEN FILED WITH
THE SECRETARY OF THE COMMISSION WITHOUT THE ▇▇▇▇ PURSUANT TO THE COMPANY'S
APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
ATTACHMENT II
KEY CONTACT LIST
NAME TITLE ROLE DEPT. LOCATION TELEPHONE MAIL FAX NUMBER
DROP CODE
---------------------------------------------------------------------------------------------------------------------------------
DURA
To be provided by
Dura
ATTACHMENT III
MATERIAL SAFETY DATA SHEETS
MSDS ▇▇▇ ▇▇▇▇▇
&
Company
Material Safety Data Sheet
▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇▇▇▇▇
NAME: Cephalexin Hydrochloride Tablets
DATE: May 12, 1993
------------------------------Section 1 - MATERIAL IDENTIFICATION---------------
U.S. TELEPHONE NUMBERS: EMERGENCY ▇▇▇-▇▇▇-▇▇▇▇ CHEMTREC ▇▇▇-▇▇▇-▇▇▇▇
As of the date of issuance, we are providing available information relevant to
the handling of this material in the workplace. All information contained
herein is offered with the good faith belief that it is accurate. THIS MATERIAL
SAFETY DATA SHEET SHALL NOT BE DEEMED TO CREATE ANY WARRANTY OF ANY KIND
(INCLUDING WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE). In
the event of an adverse incident associated with this material, this safety data
sheet is not intended to be a substitute for consultation with appropriately
trained personnel. Nor is this safety data sheet intended to be a substitute
for product literature which may accompany the finished product.
See attached glossary for abbreviations.
Common Name: Cephalexin Hydrochloride Tablets
Lilly Nos.: TA4142, TA4143, TA4145
Chemical Name: 7-(D-2-Amino-2-phenylacetamido)-3-methyl-3-cephem-4-carboxylic
acid hydrochloride monohydrate; 5-Thia-1-azabicyclo[4.2.0]oct-2-
ene-2-carboxylic acid, 7-[(aminophenylacetyl)amino]-3-methyl-8-
oxo-, monohydrochloride, monohydrate, [6R-[6alpha, 7beta(R*)] ]-
Synonyms/Trade Names: Cephalexin Hydrochloride; Cephalexin; Cephalexin
Page 1
NAME: Cephalexin Hydrochloride Tablets
DATE: May 12, 1993
----------------------Section 1 - MATERIAL IDENTIFICATION (continued)-----------
Hydrochloride Tablet Mix; Cephalexin Hydrochloride Core
Tablets; Keftab*; Keftab Tablets*; LSN061188
Formulation; 4142; 4143
Mixture Ingredients Listed Below:
Percent in
Common or Chemical Name Synonyms/Trade Names CAS Number Mixture
------------------------ -------------------- ---------- ----------
Cephalexin hydrochloride Keftab* 105879-42-3 44-97
Excipients NA NA 3-55
Contains no hazardous components (one percent or greater) or carcinogens (one-
tenth percent or greater) not listed above.
*Trademark of ▇▇▇ ▇▇▇▇▇ and Company
--------------------------------------Section 2 - PHYSICAL DATA-----------------
Appearance: White to off-white powder finished as coated tablets
Odor: Odorless
Boiling Point: NA
Melting Point: NAIF
Specific Gravity: NAIF
pH: NAIF
Evaporation Rate: NAIF
Page 2
NAME: Cephalexin Hydrochloride Tablets
DATE: May 12, 1993
------------------------------Section 2 - PHYSICAL DATA (continued)-------------
Solubility in Water: Soluble
Vapor Density: NAIF
Vapor Pressure: NAIF
----------------------------Section 3 - FIRE AND EXPLOSION INFORMATION----------
Extinguishing Media: Use water, carbon dioxide, dry chemical, foam, or Halon.
Unusual Fire and Explosion Hazards: None known.
Flash Point: NAIF
Method: NA
UEL: NAIF
LEL: NAIF
--------------------------------Section 4 - REACTIVITY INFORMATION--------------
Stability: Stable at normal temperatures and pressures.
Incompatibility: May react with strong oxidizing agents (e.g.,
peroxides, permanganates, nitric acid, etc.).
Hazardous Decomposition: May emit toxic fumes when heated to decomposition.
Hazardous Polymerization: Will not occur.
Page 3
NAME: Cephalexin Hydrochloride Tablets
DATE: May 12, 1993
----------------------------Section 5 - HEALTH HAZARD INFORMATION---------------
HUMAN - OCCUPATIONAL
Effects, Including Signs and Symptoms, of Exposure: Tablets are intended for
human consumption under guidance of a physician. Tablets are not
considered hazardous under normal handling procedures. Severe
allergic reactions have been reported with occupational exposure to
cephalosporins. Effects of exposure to powder used to make tablets
may include rash, upper airway congestion, gastrointestinal upset, eye
irritation or anaphylactic shock.
Medical Conditions Aggravated By Exposure: Penicillin or cephalosporin
hypersensitivity.
Primary Route(s) of Entry: Inhalation and skin contact.
Exposure Guidelines: PEL and TLV not established.
LEG LESS THAN 100 micrograms/m3 TWA for 12 hours
ANIMAL TOXICITY DATA SINGLE EXPOSURE
Data for the active ingredient, cephalexin hydrochloride, are reported.
Oral: Cephalexin hydrochloride - Rat, median lethal dose 5000 mg/kg,
reduced activity, diarrhea.
Skin: Cephalexin hydrochloride - Rabbit, 200 mg/kg, no deaths or
toxicity.
Inhalation: Cephalexin hydrochloride - Rat, 497.5 mg/m3 for one hour, no
deaths.
Skin Contact: Cephalexin hydrochloride - Rabbit, nonirritant
Eye Contact: Cephalexin hydrochloride - Rabbit, irritant
ANIMAL TOXICITY DATA REPEAT EXPOSURE
No data are available for cephalexin hydrochloride. Toxicity data for
cephalexin monohydrate are presented.
Page 4
NAME: Cephalexin Hydrochloride Tablets
DATE: May 12, 1993
-----------------Section 5 - HEALTH HAZARD INFORMATION (continued)--------------
Target Organ Effects: Cephalexin monohydrate - None identified.
Other Effects: Cephalexin monohydrate - Salivation and vomiting.
Reproduction: Cephalexin monohydrate - No reproductive or developmental
effects.
Sensitization: Cephalexin monohydrate - NAIF
Mutagenicity: Cephalexin monohydrate - Not mutagenic in bacterial cells.
Carcinogenicity: No carcinogenicity data found. Not listed as carcinogenic
by IARC, NCI/NTP, ACGIH, or OSHA.
---------------------Section 6 - EMERGENCY AND FIRST AID PROCEDURES-------------
Eyes: Hold eyelids open and flush with a steady, gentle stream of water for
15 minutes. See an ophthalmologist (eye doctor) or other physician
immediately.
Skin: Remove contaminated clothing and clean before reuse. Wash all exposed
areas of skin with plenty of soap and water. Get medical attention if
irritation develops.
Inhalation: Move individual to fresh air. Get medical attention if breathing
difficulty occurs. If not breathing, provide artificial
respiration assistance (mouth-to-mouth) and call a physician
immediately.
Ingestion: Do not induce vomiting. Call a physician or poison control
center. If available, administer activated charcoal (6-8 heaping
teaspoons) with two to three glasses of water. Do not give
anything by mouth to an unconscious person. Immediately
transport to a medical care facility and see a physician.
Page 5
NAME: Cephalexin Hydrochloride Tablets
DATE: May 12, 1993
----------------------------------Section 7 - HANDLING PRECAUTIONS--------------
Coated compressed tablets are not considered hazardous under normal handling
procedures. The following are recommended for a production setting:
Respiratory Protection: Use an approved respirator.
Eye Protection: Chemical goggles and/or face shield.
Ventilation: Laboratory fume hood or local exhaust ventilation.
Other Protective Equipment: Chemical-resistant gloves and body covering to
minimize skin contact. If handled in a ventilated
enclosure, as in a laboratory setting, respirator
and goggles or face shield may not be required.
Safety glasses are always required.
Other Handling Precautions: In production settings, airline-supplied, hood-
type respirators are preferred. Shower and change
clothing if skin contact occurs.
--------------------Section 8 - SPILL, LEAK, AND DISPOSAL PROCEDURES------------
Spills: Contain dry material by sweeping up or vacuuming. Vacuuming may
disperse dust if appropriate dust collection filter is not part of the
vacuum. Be aware of potential for dust explosion when using
electrical equipment. Wear protective equipment, including eye
protection, to avoid exposure (see Section 7 for specific handling
precautions).
Waste Disposal: Dispose of any cleanup materials and waste residue according
to applicable federal, state, and local regulations.
Page 6
NAME: Cephalexin Hydrochloride Tablets
DATE: May 12, 1993
---------------------------------Section 9 - SHIPPING INFORMATION---------------
(Proper Shipping Name / Hazard Class / UN Number)
DOT: Not regulated for surface transport.
ICAO: Not regulated for air transport.
IMO: Not regulated for water transport.
--------------------------------------------------------------------------------
For additional information call: Occupational Health and Safety
▇▇▇ Lilly and Company ▇▇▇-▇▇▇-▇▇▇▇
For additional copies call: Customer Services
▇▇▇ ▇▇▇▇▇ and Company 1-800-LILLY-Rx
(▇-▇▇▇-▇▇▇-▇▇▇▇)
Page 7
GLOSSARY
Abbreviations Used in Material Safety Data Sheets
ACGIH = American Conference of Governmental Industrial Hygienists
BEI = Biological Exposure Index
CAS Number = Chemical Abstract Service Registry Number
CERCLA = Comprehensive Environmental Response Compensation and Liability Act
(of 1980)
CHEMTREC = Chemical Transportation Emergency Center
CWA = Clean Water Act
DOT = Department of Transportation
EP = Extraction Procedure as defined under RCRA Regulations
EPA = Environmental Protection Agency
HEPA = High Efficiency Particulate Air (Filter)
HSDB = Hazardous Substance Data Base
IARC = International Agency for Research on Cancer
ICAO = International Civil Aviation Organization
IMO = International Maritime Organization
LEG = Lilly Exposure Guideline
LEL = Lower Explosive Limit
MSDS = Material Safety Data Sheet
NA = Not Applicable, except in Section 9 where NA = North America
NAIF = No Applicable Information Found
NCI/NTP = National Cancer Institute/National Toxicology Program
NIOSH = National Institute for Occupational Safety and Health
NOS = Not Otherwise Specified
OHS = Occupational Health Services
OSHA = Occupational Safety and Health Administration
PEL = Permissible Exposure Limit
PSN = Proper Shipping Name
RCRA = Resource Conservation and Recovery Act
RTECS = Registry of Toxic Effects of Chemical Substances
▇▇▇▇ = Superfund Ammendments and Reauthorization Act
STEL = Short Term Exposure Limit
TLV = Threshold Limit Value
TSCA = Toxic Substances Control Act
TWA = Time Weighted Average/8 Hours Unless Otherwise Noted
UEL = Upper Explosive Limit
UN = United Nations
MSDS ▇▇▇ Lilly
&
Company
Material Safety Data Sheet
▇▇▇▇▇ ▇▇▇▇▇▇▇▇▇ ▇▇▇▇▇▇, ▇▇▇▇▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇▇ ▇▇▇▇▇
NAME: Cefaclor Capsules and Tablets
REVISED DATE: August 16, 1993
------------------------------Section 1 - MATERIAL IDENTIFICATION---------------
SECTIONS REVISED: Common Name, Identifiers, ▇▇▇▇▇▇▇ ▇, ▇, ▇, ▇, ▇, ▇
▇.▇. TELEPHONE NUMBERS: EMERGENCY ▇▇▇-▇▇▇-▇▇▇▇ CHEMTREC ▇▇▇-▇▇▇-▇▇▇▇
As of the date of issuance, we are providing available information relevant to
the handling of this material in the workplace. All information contained
herein is offered with the good faith belief that it is accurate. THIS MATERIAL
SAFETY DATA SHEET SHALL NOT BE DEEMED TO CREATE ANY WARRANTY OF ANY KIND
(INCLUDING WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE). In
the event of an adverse incident associated with this material, this safety data
sheet is not intended to be a substitute for consultation with appropriately
trained personnel. Nor is this safety data sheet intended to be a substitute
for product literature which may accompany the finished product.
See attached glossary for abbreviations.
Common Name: Cefaclor Capsules and Tablets
Lilly Nos.: PU3060, PU3061, PU3062, QA252N, QA446J, TA4059,
TA4074, TA4075, TA4220, TA4221, TA4222, UC5004,
UC5005, UC5018, UC5368, UC5369, UC5902, UE0007,
UE0008, UE0020, UE0021, VF0075, VF0078, VF0258,
VF0259, VF0272, VF0277, VF0278, VF0307, VF0308,
VF0309, VF0310, VF0325
Page 1
NAME: Cefaclor Capsules and Tablets
REVISED DATE: August 16, 1993
-------------------Section 1 - MATERIAL IDENTIFICATION (continued)--------------
Chemical Name: 5-Thia-1-azabicyclo [4.2.0] oct-2-ene-2-carboxylic acid, 7-
[(aminophenylacetyl)amino]-3-chloro-8-oxo-, monohydrate, [(6R-
[6alpha,7beta(R*)]]-; 3-Chloro-7-D-(2-phenylglycinamido)-3-
cephem-4-carboxylic acid monohydrate
Synonyms/Trade Names: Cefaclor; Cefaclor Capsule Mix; Cefaclor Capsules;
Cefaclor Tablet Mix; Cefaclor Tablets; Cefaclor
Convenient Dose Tablet; Cefaclor Extended Release
Tablet; Cefaclor Chewable Tablet; Ceclor*; Ceclor CD*;
Ceclor AF*; Ceclor Pulvules*; Ceclor Tablets*;
LSN099638 Formulation; Panoral*; Panacef*; Kefral*;
Alfatil*; Keflor*; Distaclor*; Kefolor*; Kefalor*;
Ceclor*; 3061, 3062; 7250; 7500; Cefaclor MR; Cefaclor
CD; Cefaclor AF; Alfatil Gelules; Alfatil LP; Kloclor;
Kloclor BD
Mixture Ingredients Listed Below:
Percent in
Common or Chemical Name Synonyms/Trade Names CAS Number Mixture
----------------------- -------------------- ---------- ----------
Cefaclor Ceclor* ▇▇▇▇▇-▇▇-▇ 13-92
Excipients NA NA 8-87
Contains no hazardous components (one percent or greater) or carcinogens (one-
tenth percent or greater) not listed above.
*Trademark of ▇▇▇ ▇▇▇▇▇ and Company
---------------------------------------Section 2 - PHYSICAL DATA----------------
Appearance: Capsules containing white to off-white powder or white to off-
white powder finished as blue film-coated tablets
Odor: Odorless
Boiling Point: NA
Melting Point: NA
Specific Gravity: NA
pH: NAIF
Page 2
NAME: Cefaclor Capsules and Tablets
REVISED DATE: August 16, 1993
--------------------------------Section 2 - PHYSICAL DATA (continued)-----------
Evaporation Rate: NAIF
Solubility in Water: Slightly soluble
Vapor Density: NAIF
Vapor Pressure: NAIF
------------------------Section 3 - FIRE AND EXPLOSION INFORMATION--------------
Extinguishing Media: Use water, carbon dioxide, dry chemical, foam, or Halon.
Unusual Fire and Explosion Hazards: As a finely divided material, may form dust
mixtures in air which could explode if subjected to an ignition
source. May emit toxic chloride fumes when heated to
decomposition.
Flash Point: NAIF
Method: NA
UEL: NAIF
LEL: NAIF
------------------------------Section 4 - REACTIVITY INFORMATION----------------
Stability: Stable at normal temperatures and pressures.
Incompatibility: May react with strong oxidizing agents (e.g., peroxides,
permanganates, nitric acid, etc.).
Hazardous Decomposition: May emit toxic chloride fumes when heated to
decomposition.
Hazardous Polymerization: Will not occur.
Page 3
NAME: Cefaclor Capsules and Tablets
REVISED DATE: August 16, 1993
----------------------------Section 5 - HEALTH HAZARD INFORMATION---------------
HUMAN - OCCUPATIONAL
Effects, Including Signs and Symptoms, of Exposure: Capsules and tablets are
intended for human consumption under guidance of a physician. Capsules
and coated tablets are not considered hazardous under normal handling
procedures. Effects of exposure to contents of capsule or powder used
to make tablets may include eye irritation and allergic reactions.
Based on prior experience with cephalosporin antibiotics, allergic
reactions may include rash, nasal congestion, cough, dry throat,
gastrointestinal upset, eye irritation, or anaphylactic shock.
Medical Conditions Aggravated By Exposure: Penicillin or cephalosporin
hypersensitivity.
Primary Route(s) of Entry: Inhalation and skin contact.
Exposure Guidelines: Cefaclor - PEL and TLV not established.
LEG LESS THAN 100 micrograms/m3 TWA for 12 hours
ANIMAL TOXICITY DATA SINGLE EXPOSURE
Data for the active ingredient, cefaclor, are reported.
Oral: Cefaclor - Rat, 5000 mg/kg, no deaths or toxicity.
Monkey, 1000 mg/kg, no deaths, diarrhea.
Skin: Cefaclor - Rabbit, 500 mg/kg, no deaths or toxicity.
Inhalation: Cefaclor - Rat, 224 mg/m3 for one hour, no deaths or toxicity.
Intraperitoneal: Cefaclor - Mouse, median lethal dose estimated greater
than 5000 mg/kg, mortality.
Skin Contact: Cefaclor - Rabbit, nonirritant
Eye Contact: Cefaclor - Rabbit, slight irritant
Page 4
NAME: Cefaclor Capsules and Tablets
REVISED DATE: August 16, 1993
--------------------Section 5 - HEALTH HAZARD INFORMATION (continued)-----------
ANIMAL TOXICITY DATA REPEAT EXPOSURE
Data for the active ingredient, cefaclor, are reported.
Target Organ Effects: Cefaclor - Kidney effects (dilation of renal
tubules).
Other Effects: Cefaclor - Vomiting, soft stools, and reversible
thrombocytopenia.
Reproduction: Cefaclor - No reproductive or developmental effects.
Sensitization: Cefaclor - Guinea pig, not a contact sensitizer.
Mutagenicity: Cefaclor - NAIF
Carcinogenicity: No carcinogenicity data found. Not listed as
carcinogenic by IARC, NCI/NTP, ACGIH, or OSHA.
---------------------Section 6 - EMERGENCY AND FIRST AID PROCEDURES-------------
Eyes: Flush eyes with plenty of water. Get medical attention.
Skin: Remove contaminated clothing and clean before reuse. Wash all exposed
areas of skin with plenty of soap and water. Get medical attention if
irritation develops.
Inhalation: Move individual to fresh air. Get medical attention if breathing
difficulty occurs. If not breathing, provide artificial
respiration assistance (mouth-to-mouth) and call a physician
immediately.
Ingestion: Do not induce vomiting. Call a physician or poison control center.
If available, administer activated charcoal (6-8 heaping
teaspoonfuls) with two to three glasses of water. Do not give
anything by mouth to an unconscious person. Immediately transport
to a medical care facility and see a physician.
Page 5
NAME: Cefaclor Capsules and Tablets
REVISED DATE: August 16, 1993
---------------------------------Section 7 - HANDLING PRECAUTIONS---------------
Filled capsules and coated compressed tablets are not considered hazardous under
normal handling procedures. The following are recommended for a production
setting:
Respiratory Protection: Use an approved respirator.
Eye Protection: Chemical goggles and/or face shield.
Ventilation: Laboratory fume hood or local exhaust ventilation.
Other Protective Equipment: Chemical-resistant gloves and body covering to
minimize skin contact. If handled in a ventilated
enclosure, as in a laboratory setting, respirator
and goggles or face shield may not be required.
Safety glasses are always required.
Other Handling Precautions: In production settings, airline-supplied, hood-
type respirators are preferred. Shower and change
clothing if skin contact occurs.
-------------------Section 8 - SPILL, LEAK, AND DISPOSAL PROCEDURES-------------
Spills: Contain dry material by sweeping up or vacuuming. Vacuuming may
disperse dust if appropriate dust collection filter is not part of the
vacuum. Be aware of potential for dust explosion when using
electrical equipment. Wear protective equipment, including eye
protection, to avoid exposure (see Section 7 for specific handling
precautions).
Waste Disposal: Dispose of any cleanup materials and waste residue according to
applicable federal, state, and local regulations.
Page 6
NAME: Cefaclor Capsules and Tablets
REVISED DATE: August 16, 1993
-----------------------------------Section 9 - SHIPPING INFORMATION-------------
(Proper Shipping Name / Hazard Class / UN Number)
DOT: Not regulated for surface transport.
ICAO: Not regulated for air transport.
IMO: Not regulated for water transport.
--------------------------------------------------------------------------------
For additional information call: Occupational Health and Safety
▇▇▇ ▇▇▇▇▇ and Company ▇▇▇-▇▇▇-▇▇▇▇
For additional copies call: Customer Services
▇▇▇ Lilly and Company 1-800-LILLY-Rx
(▇-▇▇▇-▇▇▇-▇▇▇▇)
Page 7
ATTACHMENT IV TO MRD
THIRD PARTY FORECAST*
FOR FINISHED PRODUCT MANUFACTURED BY LILLY
Date:
To: From:
Customer Service Company:
Phone:
phone:
fax:
Address: ▇▇▇ ▇▇▇▇▇ Industries, Inc.
Call ▇▇▇ ▇▇▇▇
▇▇▇▇▇▇ ▇▇▇▇▇▇▇
▇▇▇▇▇▇▇▇, ▇▇▇▇▇▇ ▇▇▇▇ ▇▇▇▇▇-▇▇▇▇
Attention: Customer Services, PR03
Product Title:
Item Code:
Current Calendar
Year and Next
by Month Requested Qty PO Qty PO# PO Due Date/Comments
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
Calendar Year
Next (May be partially listed by month
above)
Yr After
*To be provided monthly by Lilly
ATTACHMENT V
PRODUCT SPECIFICATIONS
[Graphic representation: beakers and test tubes with LILLY ADMIN LIMS in a
circle]
▇▇▇ ▇▇▇▇▇ AND COMPANY
PRODUCT SPECIFICATION DOCUMENT
TA4220
Tablets No. 4220 CECLOR CD, 375 (Cefaclor, Convenient Dose Tablets)
As of: 20-AUG-1996
Printed Date: 20-AUG-1996 12:40
Program: AL_SM_PROD_SPEC_DOC
Distribute to: ▇▇▇▇▇, ▇▇▇▇▇▇ Drop Code: 80PI
TA4220
▇▇▇ ▇▇▇▇▇ AND COMPANY
PRODUCT SPECIFICATION DOCUMENT
As of: 20-AUG-1996
TITLE: Tablets No. 4220 CECLOR CD. 375 (Cefaclor, Convenient Dose Tablets)
--------------------------------------------------------------------------------
FORMULATION DESC: STANDARD
COUNTRY: UNITED STATES OF AMERICA
CAUTIONS: Intact Cefaclor Capsules and Tablets are not considered to be a health
hazard. Cefaclor Capsules and Tablets contains cefaclor which may be
irritating to the eyes and causes severe allergic reactions.
DESCRIPTION: A compressed, modified paracapsule shape, dual radii, size 3,
blue film-coated tablet imprinted with the script Lilly, Ceclor
CD 375 with edible black ink.
STORAGE REQUIREMENTS: Refer to Corporate Product Dating and Storage Manual
for current storage requirements.
EXPIRATION PERIOD: Refer to Corporate Product Dating and Storage Manual for
current dating
REGULATORY STATUS: NDA 50-673
CONTAINERS: Refer to current Master Packaging Order(s) for approved
container/closure systems.
HANDLING: N/A
HOUSE SAMPLE STORAGE INSTRUCTIONS: For finished trade package(s) sample removal
refer to departmental procedure GN-0093-OQC.
STANDARDS:
MANUFACTURED
Standard Testing Stage: AFTER COATING
CEFACLOR
Molecular Formula: ▇▇▇ ▇▇▇ ▇▇ ▇▇ ▇▇ ▇.▇▇▇
▇▇▇ Ingrd Label Amount: 375 % Excess: 1
Act Ingrd Label Units: mg/Tablet
ACCEPTANCE Spec: 100179-3
Method: B00402 HPLC: REVERSE PHASE
Comments: N=10, N=30 (YP FROM S-70)
NLT 356.3 mg/Tablet
Cefaclor (95.0%)
NMT 405.0 mg/Tablet
Cefaclor (108.0%)
REGULATORY Spec: 100180-2
Method: B00402 HPLC: REVERSE PHASE
NLT 337.5 mg/Tablet
CEFACLOR (90.0%)
NMT 412.5 mg/Tablet
CEFACLOR (110.0%)
DISSOLUTION
INFORMATIONAL Spec: 100775-1
Method: B00416 UV
Units:
Qualifier: AT 3 HOURS
EQUAL TO RESULTS AT 3 HOURS
NO LIMITS
Page 2 TA4220
As of: 20-AUG-1996
TITLE: Tablets No. 4220 CECLOR CD. 375 (Cefaclor, Convenient Dose Tablets)
--------------------------------------------------------------------------------
Standard Testing Stage: AFTER COATING (Continued)
DISSOLUTION (Continued)
REGULATORY Spec: 100183-1
Method: B00416 UV
NLT 20% AND NMT 50%, 60 MINUTES.
REGULATORY Spec: 100184-1
Method: B00416 UV
NLT 80%, 240 MINUTES
REGULATORY Spec: 100295-1
Method: B00416 UV
NLT 5% AND NMT 30%, 30 MINUTES
IC CEFACLOR
REGULATORY Spec: 100187-2
Method: B00402 HPLC: REVERSE PHASE
RETENTION TIME OF SAMPLES COMPARES WITH THAT OF THE REFERENCE
STANDARD.
REL SUBS
REGULATORY Spec: 100189-1
Method: B00379 HPLC: GRADIENT
Comments: TOTAL
NMT 4.0 Percent
Related Substances Total
REL SUBS: INDIVIDUAL
REGULATORY Spec: 100188-1
Method: B00379 HPLC: GRADIENT
Comments: INDIVIDUAL
NMT 1.0 Percent
Related Substances: Individual
UNIFORMITY OF DOSAGE UNITS
ACCEPTANCE Spec: 101312-1
Method: B00402 HPLC: REVERSE PHASE
Comments: N=10, N=30
95%/95% Tolerance limits for Cefaclor are within 85.0-115.0% of
the USP Reference Value and no critical dosage unit.
REGULATORY Spec: 101313-1
Method: B00402 HPLC: REVERSE PHASE
Comments: N=10,N=30
Meets USP content uniformity requirements
WATER
REGULATORY Spec: 100190-1
Method: B0024 ▇▇▇▇ ▇▇▇▇▇▇▇
NMT 6.5 Percent
Water
Page 3 TA4220
As of: 20-AUG-1996
TITLE: Tablets No. 4220 CECLOR CD. 375 (Cefaclor, Convenient Dose Tablets)
--------------------------------------------------------------------------------
Standard Testing Stage: AFTER PACKAGING
PHYSICAL APPEARANCE
ACCEPTANCE Spec: 100191-1
Method: A02637
It is a blue tablet, imprinted with the script Lilly, Ceclor CD
375 with black ink.
TA4221
PAGE 1 OF 3
▇▇▇ ▇▇▇▇▇ AND COMPANY
PRODUCT SPECIFICATIONS
TITLE: TABLETS NO. 4221 CECLOR CD, 500 MG (CEFACLOR CONVENIENT DOSE TABLETS)
Rev. No. 1.1 (Effective date to be determined)
CAUTIONS: Eye irritant. Allergen. Digestive effects. Detailed hazard
information for this item should be obtained from the material safety
data sheets on the VTX system or from other local official source, if
VTX is not available.
REASON FOR THIS REVISION:
1. Transfer the before coating assays to the after coating stage.
DESCRIPTION: A compressed, modified paracapsule shape, dual radii, size 4,
blue film-coated tablet imprinted with the script Lilly, Ceclor
CD 500 with edible black ink.
ADDED SUBSTANCES: NONE
REGULATORY STATUS: NDA 50-673
DATING AND STORAGE: Refer to "Corporate Product Dating and Storage Manual" for
Current dating and storage requirements.
CONTAINERS: Refer to current Master Packaging Orders for the approved
container/ closure systems.
HANDLING: N/A
STANDARDS:
After Coating Acceptance Limits Regulatory Limits
------------- ----------------- -----------------
Cefaclor 475.0-540.0mg/tab 450.0-550.0mg/tab
C15H14CIN3O4S _ H20 (95.0 - 108.0%) (90.0 - 110.0%)
Excess - 1% Label claim 500 mg/tab
Combined estimated Mean from
S-70
HPLC Method
TA4221
PAGE 2 OF 3
TABLETS NO. 4221 CECLOR CD 500 MG
Rev. No. 1.1 (Effective date to be determined)
After Coating Acceptance Limits Regulatory Limits
------------- ----------------- -----------------
Uniformity of Dosage Units (CASE A): 95%/95% tolerance Meets USP Test
by content uniformity limits for Cefaclor are within
HPLC Method 85.0 - 115.0% of the USP ref.
value and no. critical dosage
unit samples.
Dissolution NLT 5% and NMT 30% dissolved NLT 5% and NMT than
in 30 minutes, NLT 20% and NMT 30% dissolved in 30
50% dissolved in 60 minutes, minutes, NLT 20%
and NLT 80% dissolved in 240 and NMT 50%
minutes. dissolved in 60
minutes, and NLT
80% dissolved in
240 minutes.
Meets USP
Acceptance
Criteria.
-Canada
requirements:
NLT 40% dissolved
in 120 min.
Identification Same as Regulatory Retention time of
(Cefaclor) samples compares
HPLC Method with that of the
reference standard
Related Substances NMT 1.0% Individual Not more than 1.0 %
HPLC Method NMT 4.0% Total individual related
substance and not
more than 4.0%
total related
substance
Canada
Requirements:
NMT 0.5% Individual
NMT 2.0% Total
Water (▇▇▇▇ ▇▇▇▇▇▇▇) Same as Regulatory Not more than 6.5%
AFTER FINISHING:
Physical appereance: Each packaging order will be visually identified by size,
shape, color and logo by Quality Control.
OTHER IMPORTANT INFORMATION:
House sample -- for finished trade package(s) sample removal refer to
departmental procedure GN-0093-OQC.
TA4221
PAGE 3 OF 3
TABLETS NO. 4221 CECLOR CD 500 MG
Rev. No. 1.1 (Effective date to be determined)
OTHER IMPORTANT INFORMATION:
Informational only:
Dissolution For informational purposes 120 and 180
(Additional) min will be run.
Written by: ▇. ▇▇▇▇▇
QC REP PR03
08/20/96
[Graphic representation: beakers and test tubes with LILLY ADMIN LIMS in a
circle]
▇▇▇ ▇▇▇▇▇ AND COMPANY
PRODUCT SPECIFICATION DOCUMENT
TA4143
Tablets No. 4143 Keftab, 500 mg (Cephalexin Hydrochloride Tablets)
As of: 20-AUG-1996
Printed Date: 20-AUG-1996 12:40
Program: AL_SM_PROD_SPEC_DOC
Distribute to: ▇▇▇▇▇, ▇▇▇▇▇▇ Drop Code: 80PI
TA4143
DISTA PRODUCTS COMPANY
PRODUCT SPECIFICATION DOCUMENT
As of: 20-AUG-1996
TITLE: Tablets No. 4143 Keftab, 500 mg (Cephalexin Hydrochloride Tablets)
--------------------------------------------------------------------------------
FORMULATION DESC: STANDARD
COUNTRY: UNITED STATES OF AMERICA
CAUTIONS: Intact Cephalexin Hydrochloride Tablets are not considered to be a
health hazard. Cephalexin Hydrochloride Tablets contains cephalexin
hydrochloride which may be irritating to the eyes and causes severe
allergic reactions.
DESCRIPTION: An elliptical shaped, dark green, sugar coated tablet imprinted
with "KEFTAB 500".
STORAGE REQUIREMENTS: Refer to the Corporate Product Dating and Storage
Manual for current dating. Refer to the Corporate
Product Dating and Storage Manual for current storage
requirements.
EXPIRATION PERIOD: Refer to the Corporate Product Dating and Storage Manual for
current dating.
REGULATORY STATUS: NDA 50-614
ADDED SUBSTANCES: None
CONTAINERS: Refer to the current Master Packaging Order(s) for approved
container/closure system(s).
HANDLING: Expensive
HOUSE SAMPLE STORAGE INSTRUCTIONS: Finished trade package(s) of at least 100
tablets from each packaging order.
STANDARDS:
MANUFACTURED
Standard Testing Stage: BEFORE COATING
CEPHALEXIN
Molecular Formula: C16 H17 N3 O4 S
ACCEPTANCE Spec: 14679-3
Method: A14040HPLC
Comments: Combined estimate mean from ▇-▇▇, ▇▇▇▇,▇▇▇▇
▇▇▇ 475.0 mg/Tablet
95.0 %
NMT 540.0 mg/Tablet
108.0%
REGULATORY Spec: 14682-3
Method: A14040HPLC
Comments: Combined estimate mean from S-70,N=10,N=30
NLT 450.0 mg/Tablet
90.0%
NMT 550.0 mg/Tablet
110.0%
UNIFORMITY OF DOSAGE UNITS
ACCEPTANCE Spec: 14690-2
Method: A14040HPLC
CASE A; 95/95 tolerance limits for Cephalexin within 85.0-115.0%
of the USP Reference value and no critical dosage unit samples.
REGULATORY Spec: 14693-2
Method: A14040HPLC
Meets USP content uniformity requirements
Page 2 TA4143
As of: 20-AUG-1996
TITLE: Tablets No. 4143 Keftab, 500 mg (CephalexIn Hydrochloride Tablets)
--------------------------------------------------------------------------------
Standard Testing Stage: AFTER COATING
CEPHALEXIN
Molecular Formula: C16 H17 N3 O4 S
ACCEPTANCE Spec: 14704-3
Method: A14040HPLC
Comments: Composite sample, N=20
NLT 475.0 mg/Tablet
95.0 %
NMT 540.0 mg/Tablet
108.0 %
REGULATORY Spec: 14706-3
Method: A14040HPLC
Comments: Composite sample, N=20
NLT 450.0 mg/Tablet
90.0 %
NMT 550.0 mg/Tablet
110.0 %
DISSOLUTION
REGULATORY Spec: 14707-1
Method: B00344 ROTATING BASKET
NLT 75% Q/45 minutes
ID CEPHALEXIN
ACCEPTANCE Spec: 102117-1
Method: A14040HPLC
The retention time of the Cephalexin peak from the sample
chromatogram compares qualitatively with the reference standard
chromatogram obtained in the same manner..
REGULATORY Spec: 101682-1
Method: A01254IR
The sample spectrum compares qualitatively with the reference
standard obtained in the same manner.
WATER
REGULATORY Spec: 14709-1
Method: A09475KARL ▇▇▇▇▇▇▇
NMT 8.0 Percent
Standard Testing Stage: AFTER PACKAGING
PHYSICAL APPEARANCE
ACCEPTANCE Spec: 14710-2
Method: A02637
It is an elliptical shaped, dark green, coated tablet imprinted
with KEFTAB 500 packaged as an Identi-Dose or in an amber plastic
bottle.
*** End of Report ***
MRD
ATTACHMENT VI
PRICES OF PRODUCTS AND SAMPLES
(a) *** will be invoiced at the following prices:
Product Price
------- -----
Ceclor CD
*** Bottles of 60 Tablets ***
*** Bottles of 60 Tablets ***
Keftab
500 mg Bottles of 100 Tablets ***
(b) *** will be invoiced at the following prices:
Keftab 500 mg 2 x 2 Samples *** per Sample
Ceclor CD *** 2 x 2 Samples *** per Sample
(c) Beginning *** and on *** shall *** the *** in *** for such
presentations (determined in accordance with *** consistently
applied), but in no case *** for any Product (including samples of
Product) *** shall give *** notice on or before *** of any and all ***
with said *** to be effective *** received after *** of the ***
(d) Any modifications or adjustments to any of the prices set forth on the
Exhibit C for reasons other than those described in paragraph (c),
above, shall be evidenced in writing and be executed by an authorized
representative of each party.
--------------------------------------
* CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED BY MEANS OF MARKING
SUCH PORTIONS WITH AN ASTERISK (THE "▇▇▇▇"). THIS EXHIBIT HAS BEEN FILED WITH
THE SECRETARY OF THE COMMISSION WITHOUT THE ▇▇▇▇ PURSUANT TO THE COMPANY'S
APPLICATION REQUESTING CONFIDENTIAL TREATMENT UNDER RULE 24b-2 UNDER THE
SECURITIES EXCHANGE ACT OF 1934, AS AMENDED.
APPENDIX B TO MANUFACTURING AGREEMENT
TRANSITION PLAN
Dura and Lilly each acknowledge and agree that good faith coordination and
cooperation between them are essential to ensure as problem-free a transition as
possible after the Closing Date. To that end, Dura and Lilly hereby agree that,
from and after the Closing Date:
1. Dura shall fulfill all contractual pricing offered by Lilly on the Products
for a period of time which shall not, for any applicable contract, end
earlier than (a) the requisite period of notice that Lilly is required to
provide under such contract in order to delete the Product from the
contract plus thirty (30) days, or (b) the expiration or other termination
of such contract. Lilly has provided Dura with all such contractual
pricing information.
2. If any Ceclor CD or Keftab sample units or labeling does not reflect Dura
as the distributor, then Dura shall affix stickers containing Dura's new
NDC codes, in a form approved by the FDA, to such Products (including
samples thereof) bearing a Lilly label prior to selling and shipping such
Product.
3. Lilly shall notify by letter within two (2) days of the Closing Date (the
form and content of which shall be mutually agreed upon by Dura and Lilly)
all applicable Lilly customers of the change in the distribution of the
Products.
4. (a) Subject to the provisions of paragraph (d) of this Section 4, Lilly
shall be responsible for Products sold by Lilly, and for the
administration and payment of all Medicaid rebates and other
governmental assistance programs conditional upon payment of rebates
and similar programs in which a Product sold by Lilly is involved; and
Dura shall be responsible for Products sold by Dura, and for the
administration and payment of all Medicaid rebates and other
governmental assistance programs conditional upon payment of rebates
in similar programs in which a Product sold by Dura is involved.
(b) Subject to the provisions of paragraph (d) of this Section 4, Lilly
shall be responsible for administration and payment of all wholesaler
chargebacks involving Products sold by Lilly prior to the Closing
Date, and Dura shall be responsible for administration and payment of
all wholesaler chargebacks involving Products sold by Dura on or after
the Closing Date.
(c) Except as set forth in Section 7.12 of the Licensing Agreement and
subject to the provisions of paragraph (d) of this Section 4,
(Page 1 of 2)
Dura shall be responsible for all returns of Products sold on or after
the Closing Date, and Lilly shall be responsible for returns of
Product sold before the Closing Date.
(d) Notwithstanding the provisions of paragraphs (a), (b) and (c) of this
Section 4, but subject to the provisions of Section 7.12 of the
Licensing Agreement, if the parties are unable to determine whether a
Product was sold by Lilly or by Dura, then Lilly shall be responsible
for any and all rebates, chargebacks and returns received during the
sixty (60) day period following the Closing Date, and Dura shall be
responsible thereafter.
5. Dura and Lilly each shall in good faith cooperate and coordinate as
necessary to accomplish all of the foregoing and shall otherwise each do
all other things as may be reasonably necessary to accomplish the
transition contemplated herein.
Dura/Manufacturing Agreement/Exhibit B-8/20/96
(Page 2 of 2)